These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25946901)

  • 1. Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma.
    Riet T; Abken H
    Expert Rev Hematol; 2015 Aug; 8(4):383-5. PubMed ID: 25946901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic engineering of T cells in leukemia and lymphoma.
    Kochenderfer JN
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):190-2. PubMed ID: 24927269
    [No Abstract]   [Full Text] [Related]  

  • 3. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
    Frey NV; Porter DL
    Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
    Enblad G; Karlsson H; Gammelgård G; Wenthe J; Lövgren T; Amini RM; Wikstrom KI; Essand M; Savoldo B; Hallböök H; Höglund M; Dotti G; Brenner MK; Hagberg H; Loskog A
    Clin Cancer Res; 2018 Dec; 24(24):6185-6194. PubMed ID: 30097433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias.
    Khan M; Mansoor AE; Olson AL
    Future Oncol; 2016 Oct; 12(19):2179-82. PubMed ID: 27250512
    [No Abstract]   [Full Text] [Related]  

  • 8. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Orlowski RJ; Porter DL; Frey NV
    Br J Haematol; 2017 Apr; 177(1):13-26. PubMed ID: 27977050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
    Kasenda B; Kühnl A; Chau I
    Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.
    Abken H
    Immunotherapy; 2015; 7(5):535-44. PubMed ID: 26065478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status and future development of CAR-T gene therapy].
    Ozawa K
    Rinsho Ketsueki; 2015 Oct; 56(10):2180-5. PubMed ID: 26458458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
    Ozawa K
    Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.